Progression-free survival for unresectable non-metastatic locally advanced pancreatic cancer after surgical microwave ablation plus durvalumab and tremelimumab: phase-2 non-randomized prospective clinical trial.

ABSTRACT:

Background

Despite significant advancements in cancer immunotherapy, survival outcomes remain poor in patients with pancreatic ductal adenocarcinoma.

Methods

In this early phase II clinical trial, we evaluated the combined effects of immunotherapy with dual immune checkpoint inhibitors durvalumab and tremelimumab, local tumor ablation with microwave energy, and gemcitabine on progression-free survival in twelve patients with non-metastatic unresectable locally advanced pancreatic adenocarcinoma. Single-cell transcriptomics and T cell receptor profiling were used to characterize the tumor microenvironment and peripheral blood immune cell repertoire.

Results

Here we show that from these twelve patients (median progression-free survival = 8.9 months, 95% confidence inter

SUBMITTER: Topal H 

PROVIDER: S-EPMC12627779 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature